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Background: Obesity is an excessive accumulation of fat frequently, but not always, associated with health
problems, mainly type 2 diabetes and cardiovascular disease. During a positive energy balance, as caused by
excessive intake or sedentary lifestyle, subcutaneous adipose tissue expands and accumulates lipids as triglycerides.
However, the amount of adipose tissue per se is unlikely to be the factor linking obesity and metabolic
complications. The expandability hypothesis states that, if this positive energy balance is prolonged, a point is
eventually reached where subcutaneous adipose tissue can not further expand and energy surplus no longer can
be safely stored. Once the limit on storage capacity has been exceeded, the dietary lipids start spilling and
accumulate ectopically in other organs (omentum, liver, muscle, pancreas) forming lipid byproducts toxic to cells.
Methods/Design: FATe is a multidisciplinary clinical project aimed to fill gaps that still exist in the expandability
hypothesis. Imaging techniques (CT-scan), metabolomics, and transcriptomics will be used to identify the factors
that set the limit expansion of subcutaneous adipose tissue in a cohort of caucasian individuals with varying
degrees of adiposity. Subsequently, a set of biomarkers that inform the individual limits of expandability will be
developed using computational and mathematical modeling. A different validation cohort will be used to minimize
the risk of false positive rates and increase biomarkers' predictive performance.
Discussion: The work proposed here will render a clinically useful screening method to predict which obese
individuals will develop metabolic derangements, specially diabetes and cardiovascular disease. This study will also
provide mechanistic evidence that promoting subcutaneous fat expansion might be a suitable therapy to reduce
metabolic complications associated with positive energy balance characteristic of Westernized societies.
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Obesity is a chronic disease of multifactorial origin and
physiologically defined as an accumulation of fat that
causes health problems. At the population level, this ex-
cessive adiposity has been epidemiologically associated
with a wide array of metabolic complications such as
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unless otherwise stated.of cancer [1-4]. At the individual level, however, dispar-
ities do exist; some thin people are insulin resistant,
while some very obese people remain metabolically
healthy on the basis of a beneficial adipose tissue growth
[5-9]. The amount of adipose tissue per se is hence un-
likely to be the factor linking obesity and metabolic
complications.
Adipose tissue is located under the skin (subcutane-
ous) or within the abdominal wall (visceral) and
endowed with a high plasticity, being able to expand and
contract in response to changes in energy balance. Cur-
rently it is believed that the accumulation of subcutaneousntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neous fat is determined by the formation of new adipo-
cytes and the ability to expand from those already
formed [10]. The new adipocytes appear from their pre-
cursors, known as preadipocytes, vascular stroma, as
well as adipose or mesenchymal stem cells [11]. The
total number of stem cells available to differentiate into
new adipocytes determines the intrinsic limit in the adi-
pose tissue expansion, given the inability to form new
adipocytes once this "pool" of precursors is exhausted
[12]. This growth process is also based in the ability to
remodel the extracellular matrix that surrounds the adi-
pocytes and the formation of new vessels (angiogenesis)
irrigating the new cells [13]. This expansive process is
hence regulated by the coordinated expression of genes,
proteins, and metabolites from different cell types. The
recently developed theory of the expandability of adi-
pose tissue states that this expansion is not unlimited.
At some point, adipose tissue reaches its maximum
storage capacity and lipid excess is redirected to other
tissues causing lipotoxicity [14,15]. This ectopic accu-
mulation in different organs and, among them, the
peritoneum, is associated with a chronic inflammatory
condition of low intensity. Macrophages, lymphocytes,
eosinophils, natural killer (NK) and mast cells are
known to dwell in the adipose tissue, yet their precise
role needs to be elucidated [16-18].
The work proposed here will help fill gaps that still
exist in this theory and define the factors that limit ex-
pansion. Using high-throughput technologies, this study
aims to discover novel mechanisms regulating the ex-
pansion of subcutaneous adipose and how they are in-
volved in the development and progression of metabolic
complications occurring in obesity. Subsequently, a set
of biomarkers that inform the individual limits of ex-
pandability will be developed using computational and
mathematical modeling.Methods
Hypothesis
During a positive energy balance, as caused by excessive
intake or sedentary lifestyle, subcutaneous adipose tissue
expands and accumulates lipids as triglycerides. We
hypothesize that, if this situation is prolonged, a point is
eventually reached in the subcutaneous adipose tissue
where it can not further expand and energy surplus no
longer can be safely stored. Once the limit on storage
capacity has been exceeded, the dietary lipids start
spilling and ectopically accumulating in other organs
(omentum, liver, muscle, pancreas), giving rise to lipid
byproducts that are toxic to cells. Thus, adipose tissue
has a defined growth boundary for a given individual,
and this limit has a large inter-individual variability.Objectives
FATe is a clinical project with the following specific
aims: 1) Use of imaging techniques (CT-scan), metabolo-
mics, and transcriptomics to identify the factors that set
the limit expansion of subcutaneous adipose tissue in in-
dividuals with varying degrees of adiposity. 2) use those
factors to build biomarkers able predict the onset and
severity of the metabolic complications of obesity. 3)
gather a collection of biological samples (serum, plasma,
adipose biopsies, adipose RNA, and DNA) for ancillary
studies to identify new genetic and environmental deter-
minants of the association of obesity and metabolic
abnormalities.
Determination of fat expansion
The visceral and subcutaneous fat will be measured by
computer tomography (CT) with a 8mm single slice at
the umbilical level. All CT examinations will be ac-
quired with the subject positioned supine in a 64 de-
tector CT scanner (Aquilion 64 Toshiba Tokyo, Japan)
and tube voltage set to 120 kVp with automatic tube
current modulation and rotation time of 0,5 s. Acquired
images will be then transferred to a workstation and
analyzed with the Vitrea CT Fat Measurement software
(Vital Imaging Inc. The Netherlands). Selected fat dens-
ities will range between −150 and −70 Hounsfield Units
(HU) and the Total Fat Area (TFA), Subcutáneous Fat
Area (SFA) and Visceral Fat Area (VFA) will be mea-
sured in cm2. SFA and VFA are respectively defined as
pixels (area) located outside or inside the outer surface
of the abdominal muscle wall (Figure 1). Subsequently,
the ratio between subcutaneous fat area divided by the
area of visceral fat will be calculated. Operationally,
lower VFA/TFA ratios due to increased visceral lipid
deposition will be surrogates of limited ability of adi-
pose subcutaneous to further expand.
Subject participation
Ethics, consent and permissions
All patients will provide written consent according to
the Spanish 41/2002 law and the the study has been ap-
proved by the by the Regional Institutional Review
Board of Aragón. Spain. (CEIC-A).
Prospective study
The study will take place in the Hospital Universitario
Miguel Servet (HUMS) and the Hospital Royo-Villanova
(HRV), both in Zaragoza (Spain). As illustrated in the
flowchart (Figure 2), patients scheduled for laparoscopic
surgery will be offered the opportunity to participate in
the study by donating blood, biopsies of subcutaneous
adipose tissue (also visceral if the type of surgery allows)
and undergo a CT imaging test for the quantitative
determination of subcutaneous and visceral abdominal
Figure 1 Abdominal adipose tissue segmentation. Representative CT scan obtained at the umbilicus. Subcutaneous and visceral fat are colored in
blue and red, respectively.
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in Table 1. We have estimated to enroll 200 patients (150
bariatric patients) over 18 months. Biopsies (~3 cm3) of
adipose tissue from both the subcutaneous fat depot and
the great omentum will be obtained with a bipolar/ultra-
sonic device (Thunderbeat. Olympus, Spain) and extracted
via a 12 mm trocar (Applied Medical Europe, Spain) in-
serted in the left hypochondrium during laparoscopic sur-
gery. Later on, subjects will continue to receive their usual
care by their primary physician and endocrinologist with
close oversight by our research team during the first year.
Validation study
Cohort of 130 patients with the same selection criteria
who underwent the same procedures than the prospect-
ive cohort. Blood and fat biopsies have already been ob-
tained and the individuals extensively phenotyped. As
validation cohort this subjects will be annually evaluated
in the Endocrinology Service of the HUMS to study its
evolution during this period, with special emphasis in
diabetes onset and cardiovascular disease.
Characterization of cell heterogeneity by flow cytometry
To characterize different cell populations within the adi-
pose tissue, fresh fragments of both visceral and sub-
cutaneous adipose tissue biopsies will be digested with
collagenase to obtain a cell suspension. Cell size and
lipid content per adipocyte will be assessed as previously
described [19]. At least 100,000 cells in PBS with 0.5%BSA and 2 mmol/L EDTA will be incubated with
fluorescent-labeled monoclonal antibodies directed against
angiogenic, endothelial, and immune cell markers as
described [20,21]. After washing steps, the labeled cells
will be analyzed in a GALLIOS flow cytometer with the
KALUZA software (Beckman Coulter). Mesenchimal
stem cells will be considered those expressing the
CD105, CD73 and CD90 antigens and not expressing
hematopoietic cell markers CD45 and CD34.
Variables and determinations
Anthropometry and questionnaires
The variables sex, age, height, and blood pressure will be
collected at the time of the preoperative visit. Likewise, a
questionnaire will be used to asses socio-demographic
data, smoking history, consumption of alcohol or other
toxic habits, previous medical diagnosis, presence of co-
morbidities, family history of disease, and medication
use. Clinical records of each patient will be also evalu-
ated to determine the criteria for inclusion/exclusion.
Plasma biochemistry
Standard operating procedures will be deployed to as-
sure identical collection and processing for all fasting
blood samples. Extensive bloodwork will be performed
at the Clinical Biochemistry Service (HUMS) using state
of the art analyzers (Table 2). All analyses are in compli-
ance with the requirements for quality and competence
(ISO 15189:2012) for medical laboratories.
Figure 2 Flowchart for the FATe study.
Table 1 Selection criteria
Inclusion criteria Exclusion criteria
● Scheduled (non-emergency) and
laparoscopic bariatric surgery,
cholecystectomy surgery, surgical
treatment of esophageal hiatal
hernia, and abdominal hernia repair.
● Alcohol abuse
● Autoimmune diseases





diseases (HIV, HBV, HCV)
● Willingness to participate in the study
and comply with the study by signing
a written informed consent
● Available for follow-up visits over 1 year
for the prospective cohort and 4 years
for the validation cohort.
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Plasma aminoacid concentrations will be measured by
ion-exchange chromatography (IEC) with ninhydrin de-
tection. Briefly, plasma samples (1 ml) will be depro-
teinized with 0.1 ml of 35% sulfosalicilic acid (Panreac,Table 2 Core laboratory parameters
Origen Parameter
Serum Total cholesterol, Triglycerides, LDL-cholesterol,
HDL-cholesterol, Free fatty acids
Glucose, Insulin, β-hidroxibutirate, hs-CRP, Leptin
Liver Transaminases (AST, ALT, GGT)
Apolipoprotein AI, Apolipoprotein B, Lipoprotein (a)
25-Hydroxyvitamin D, Beta-CrossLaps (CTX),
Osteocalcin
Selenium
Total blood Hematimetry (Complete blood count)
Glycated Hemoglobin (HbA1c)
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then filtered trough 0.22 μm (Ultrafree Centrifugal filters.
Millipore, USA) and mixed with the same volume of 0.2 M
lithium citrate buffer, pH 2.2. (Biochrom. Germany). 20 μl
of this mixture will be injected into a Biochrom +30 system
(Biochrom), a high pressure PEEK column packed with
Ultropac 8 cation exchange resin. Aminoacids will be
eluted by varying temperature, ionic strength and pH of
the lithium citrate buffer according to the instrument
manufacturer instructions. Detection will be carried out
by the reaction of ninhydrin with amino acids to form
colored compounds. The color produced will be photo-
metrically detected at 440 nm (primary amines) and 570
nm (secondary amines). BioSys control software and
EZChrom Elite Data handling Software (Biochrom)
will be used for data acquisition and analysis. Amino
acid calibration will be prepared at know concentrations
for each analyte with commercially available standards
(Sigma) and run every time that fresh ninhydrin is
prepared.
Acylcarnitine profiling will be carried out by liquid
chromatography tandem mass spectrometry (LC-MS/
MS) system. Briefly, dried blood spots will be eluted
from filter paper with extraction solvent containing
methanol and known concentrations of stable isotopic-
ally enriched acylcarnitines (NeoBase Non-derivatized
Assay Solutions. Perkin Elmer, Finland). The eluate (10
μL) will be loaded into a Waters 2795 HPLC sample
preparation system connected to a Micromass Quattro
Micro triple-quadrupole mass spectrometer (Waters
Corp., USA). The HPLC pump provides a flow of 0.150
mL/min and injection-to-injection time is 1.7 min. The
instrument will be operated in the positive ion mode
with the following parameters: cone voltage and colli-
sion energy will range from 16 to 20 V and from 18 to
28 eV, respectively depending on the analyte, using
argon as collision gas. The ion source and desolvation
temperatures will be 120 and 350°C, respectively. Data
will be acquired using MassLynx 4.0 software (Waters
Corp.). During this acquisition, a collisionally induced
product of each analyte is measured for a set time
period and quantified based on their mass to carge
(m/z) ratio. The response of each analyte relative to
their corresponding stable-isotope labelled internal
standard will be used to quantify analyte concentration.
Plasma and erythrocyte membrane fatty acids will be
measured by gas chromatography (GC) analysis. In sum-
mary, plasma will be obtained by centrifugation of hepa-
rinized blood samples. Cell pellets, mainly erythrocytes,
will be washed with saline solution and subsequent fatty
acid extraction from both plasma and erythrocytes will be
carried out according to the modified Folch [22] method
using chloroform, methanol and 0.015M KCl (2:1:0.4,
volume to volume (v/v)) (Merk. Spain). Fatty acids in thechloroform phase will be then recovered after evaporation
under nitrogen stream followed by methylation with 5%
H2SO4 in methanol at 80°C for 90 min. Fatty acid methyl
esters will be extracted into 300 μl hexane and then
injected into an Agilent 6890 N equipped with a capil-
lary column HP-INNOWax (ref#19091N-102) and flame
ionization detector (both from Agilent Technologies, Spain).
Initial temperature for the gas chromatography will be set
at 60°C for 2 min, increased to 190°C (30°C/min), held at
200°C for 13 min, and finally increased to 240°C for
25 min. Hewlett-Packard ChemStation System software
(Hewlett-Packard, Spain) will be used for identification
of individual fatty acids by comparison with known
standards (Sigma) and expressed as a percentage of total
fatty acids quantified from peak areas.Transcriptomics
RNA sequencing (RNA-seq) analyses will be carried out
in subcutaneous biopsies with different ratios of expand-
ability calculated by CT-scan. Samples from subjects
with greater ratios (subcutaneous fat still able to expand)
will be thus compared to lower ratios (limit of expansion
already reached). Total RNA from selected biopsies will
be extracted and DNAse-treated. Library preparation
will be performed as recommended by the manufac-
turer. Samples will be sequenced to a coverage of, at
least, 40 million single-end reads of 50 bp long. The
genes of interest whose expression appears increased or
decreased will be confirmed by quantitative PCR (qPCR)
using the appropriate primers and SYBR Select Master
Mix (Applied Biosystems, USA) in a StepOnePlus Real-
Time PCR System (Applied Biosystems).
Sample biobanking
The Biobank of the Aragon Health System (BSSA) will
store all biological samples and their associated data fol-
lowing standardized protocols to ensure their viability
and reliability. Samples will be fully accessible to the
scientific community, and a laboratory informatics man-
agement applications (Bio-e-bank. Vitrosoft, Spain) has
been implemented to maintain sample traceability.
Data collection and analysis
Given i) the project lacks a single main study variable
and ii) variance estimates from omics-generated vari-
ables are unknown, the forecasted sample size is deter-
mined for our team's ability to recruit. Retrospective
analysis will be carried out to detect the power of the
differences observed in the data.
All the data collected will be incorporated into a data-
base meeting the Spanish Organic Law 15/1999 of Pro-
tection of Personal Data (LOPD). Pairwise comparisons
between continuous variables will be conducted using
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U test as appropriate. Chi square tests will be performed
for categorical variables. Pearson correlation coefficient
or Spearman Rho, according to the homogeneity of the
distribution of data, will be calculated to determine cor-
relations. For the RNA-seq analysis, the pre-processing,
quality testing, mapping, and differential gene expression
will be performed using the appropriate packages of Bio-
conductor (http://www.bioconductor.org/).
Biomarkers will be a combination of variables, mea-
sured in adipose tissue and plasma, generated by the
core biochemical analysis, multiplexed cytometry, as
well as transcriptomic and metabolomic analysis. Those
analytes will be included in a multivariate analysis;
cluster analysis, support vector machines and dimen-
sionality reduction will segregate groups that appear
differentially expressed depending on the ratios of ex-
pandability calculated by CT-scan. Subsequently, those
analytes will be modeled individually and in groups
using multivariate logistic regression where the inde-
pendent variable will be whether or not the limit of adi-
pose tissue expansion has been reached. The predictive
value of those biomarkers will be calculated using ROC
curves in the validation study. Different predictive
models adjusted for confounding variables (BMI, age)
will be described using appropriate statistical software
package R (http://cran.r-project.org/).
Discussion
We hypothesize that the accumulation of lipids in the
adipose tissue, as long as its expansive capacity is
preserved, represents an adaptive and safe way to store
energy surplus. We accordingly define dysfunctional adi-
pose tissue as not able to expand and adequately store
the surplus of lipids provided by a positive energy bal-
ance. This dysfunctional adipose tissue ultimately leads
to conditions such as metabolic syndrome, diabetes, dys-
lipidemia, and cardiovascular disease. The FAT expand-
ability (FATe) Project is an observational clinical study
aimed to elucidate the mechanisms involved in the ex-
pansion of the subcutaneous adipose tissue and find bio-
markers to determine the limit of expansion and able to
predict complications of obesity.
Mounting evidence supports that the adverse conse-
quences of obesity are strongly associated with the loca-
tion of fat accumulation, and are less dependent on the
total amount of body fat. Visceral obesity correlates with
increased risk of type 2 diabetes and cardiovascular dis-
eases, while an increase of subcutaneous fat is associated
with favorable adipokine production and improved
plasma lipid profiles [23-25]. Indeed, the accumulation
of subcutaneous adipose tissue in the gluteofemoral area
might be protective against obesity-associated metabolic
complications [26]. Consequently, it is of paramountimportance to segment this adipose tissue in more de-
fined compartments. The body mass index (BMI, weight
in kilograms divided by height in meters squared) is the
most widely used method to estimate the amount of
body fat. However, since BMI can not detect regional
variations in fat deposition, other measures able to cap-
ture abdominal obesity, such as waist circumference
(WC) or waist/hip ratio (WHR, waist circumference di-
vided by the hip circumference) are also employed. Yet,
the use of those indices can not discern the contribution
of subcutaneous adipose tissue or visceral, in abdominal
girth. The only way to differentiate these two deposits is
by imaging techniques. Currently, the only validated
techniques for measuring visceral fat are the X-ray com-
puted tomography (CT) or magnetic resonance imaging
(MRI) [27]. The longer time needed to perform MRI,
compared to CT, led us to selected the latter for this
study, given the requirement to combine the use of the
scanner for both clinical and research purposes. Our
study protocol is designed to minimize the radiation ex-
posure associated with CT without compromising ac-
curacy in estimating abdominal fat depots. Several
studies have already implemented similar methodology
proving that a single slice is enough to segment abdom-
inal fat by CT [28,29]. Some controversy still remains
regarding the point of reference. However, recent work
revealed that the measurement of the fat based on an
umbilical slice was well correlated and well concordant
with that based on a slice with a L3–L4 reference [28].
Biomarker, portmanteau of “biological marker”, refers
to any measurable indicator of metabolic processes,
ranging from heart rate or basic plasma chemistries (e.g.
glucose) to more complex constructs produced by high-
throughput techniques [30]. To the best of our knowledge,
no specific biomarkers for detection of a maxed-out sub-
cutaneous adipose tissue have been tested for prediction
in humans. We will define the calculated ratio between
the areas of visceral and subcutaneous adipose tissue as
the surrogate variable for fat expandability. The subse-
quent prospective study groups will be created according
to this variable. Then, we will begin the quest for bio-
marker discovery using a combined transcriptomic and
metabolomic approach. This holistic conceptualization
has been already proven valuable in deciphering adipose
tissue signatures related to weight changes [31]. Sequen-
cing of RNA (RNA-seq) is an emerging method of tran-
scriptomic analysis which overcome the limitations of
the hybridization-based approaches such as microarrays
[32]. Unlike the microarray technology, which quantifies
the intensity of the hybridization with a probe, RNA-seq
measures the discrete number of transcripts that are
aligned to a particular sequence. RNA-seq allows the un-
biased detection of low-expressed genes, alternative splice
variants, and novel transcripts, making this technology
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is an emerging field of -omics which is specialized in the
analysis of small metabolites (<1500 daltons) that reflect
the 'fingerprint' of the biochemical activity of the cell. Pro-
filing of plasma metabolites may therefore shed light on
the complex pathophysiological changes occurring during
adipose tissue expansion. It has been described that dif-
ferent profiles of circulating lipids can predict the risk
of cardiovascular disease [34] and insulin resistance
[35]. Interestingly, a recent work reported that fatty acids
released from necrotic adipocytes can act as powerful
adjuvants for the immune response [36].
Additionally, ectopic deposition of lipids leads to an
inflammatory response in the tissues where the depos-
ition occurs [16,17]. This response is specially important
in the visceral adipose where adipocytes anatomically
associate with lymph nodes [37]. Inflammation drives
the recruitment of other immune cells and activation of
resident M1 macrophages which, in turn, produce vari-
ous proinflammatory mediators (TNFa, IL-6, NOS) per-
petuating the inflammation [38]. This phenotype can be
reversed by IL-4-producing eosinophils able to keep
macrophages in a non-inflamatory M2-phenotype [18].
It is hence of paramount importance incorporate in our
project multiplexed flow cytometry to determine popu-
lations of immune cells within the adipose tissue and
their pro- or anti-inflammatory phenotype. We posit
that immune cell characterization coupled to gene ex-
pression information will enrich our dataset for devel-
oping multilevel biomarkers.
Integration of the data generated by high throughput
technologies using mathematical models presents quite
a few challenges. Unlike classical biomarkers (e.g. LDL
for cardiovascular disease or HER2 for breast cancer),
omics-based tests can not be explained simply on their
biological basis. Omics-based biomarkers are generated
by measuring many more variables and using multivari-
ate statistical models. These models are very likely to be
overadjusted so can result in a score that works well in
the samples used to develop the test, but inaccurately in
other samples [39]. In our study, the assessment of bio-
marker effectiveness for prediction will be separated from
biomarker discovery. To obtain an unbiased estimation,
the performance of the biomarker will be validated in
another ongoing cohort of replication. Limitation for the
validity of the biomarker might be the homogeneity in
both test and validation cohorts, all white individuals from
Spain. This phenomenon might weaken biomarker's pre-
dictive ability in other populations and would warrant to
test the performance across population subgroups.
In summary, there is currently no clinically useful screen-
ing method to predict which obese individuals will develop
metabolic derangements, specially diabetes and cardiovas-
cular disease. Indeed, available and emerging therapies toprevent obesity cannot be targeted to those high-risk indi-
viduals who likely would benefit the most. This study will
provide biomarkers based in high throughput techniques
(RNA-seq, metabolomics, multiplexed cytometry) to de-
tect impaired subcutaneous fat expandability, the under-
lying cause of pathologic obesity. To minimize the risk of
false positive rates and increase their predictive perform-
ance we will use a validation cohort. This study will also
provide mechanistic evidence that promoting fat expan-
sion might be a suitable therapy to reduce metabolic
complications associated with positive energy balance
characteristic of Westernized societies.
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